Parathyroid hormone-related protein detection and interaction with NO and cyclic AMP in the renovascular system. The presence of parathyroid hormone-related protein (PTHrP) in human kidney vasculature and the signal transduction pathways stimulated during PTHrPinduced vasodilation of the rabbit kidney were investigated. Immunostaining of human kidney revealed the abundant presence of PTHrP in media and intima of all microvessels as well as in macula densa. In isolated perfused rabbit kidney preconstricted with noradrenaline, i0 M RpcAMPS, a direct inhibitor of protein kinase A, produced comparable inhibition of 2.5 X i0 M forskolin-and i0-M PTHrP-induced vasorelaxations. Renal vasorelaxation and renal microvessel adenylyl cyclase stimulation underwent comparable desensitization following exposure to PTHrP. Nitric oxide (NO)-synthase inhibition by L-NAME (10-a M), NO scavenging by an imidazolineoxyl N-oxide (10 M) and guanylyl cyclase inhibition by methylene blue (I0-M) decreased PTHrP-induced vasorelaxation by 27 to 53%, abolished bradykinin-induced vasorelaxation and did not affect forskolin-induced vasorelaxation. The effects of RpcAMPS and L-NAME were not additive on PTHrP-induced vasorelaxation. Damaging endothelium by treating the kidney with either antifactor Vill-related antibody and complement, gossypol or detergent, did not affect PTHrP-or forskolin-induced vasorelaxations but reduced bradykinin-induced vasorelaxation by 53 to 92%. Conversely, endothelial damage did not alter the inhibitoiy action of L-NAME on PTHrP-induced vasorelaxation. In conclusion, PTHrP is present throughout the human renovascular tree and juxtaglomerular apparatus. Activation of both adenylyl cyclase/protein kinase A and NO-synthase/guanylyl cyclase pathways are directly linked to the renodilatory action of PTHrP in a way that does not require an intact endothelium in the isolated rabbit kidney.
have been shown to bind PTH with high affinity [8] . PTH also stimulates arteriolar adenylyl cyclase [7] and the release of renin [9, 10] . Despite these observations, the existence of a clear role for PTH in renovascular homeostasis remains unlikely, for there is no evidence that PTH is produced within the kidney, and it is unclear how PTH secreted by the parathyroid glands could play a meaningful role in regulation of arterial tone in the kidney.
PTH-related protein (PTHrP) was described in 1987 [reviewed in 11, 12] . PTHrP is derived from a gene that is distinct from the PTH gene yet shares striking amino acid and nucleotide homology in the amino-terminal/S '-coding region with PTH. Amino-terminal PTHrP secretoly species have been shown to bind to and act through a common PTH/PTHrP receptor that is coupled to both the adenylyl cyclase/protein kinase A and to protein kinase C/cytosolic calcium signaling pathways in bone and renal tubules. PTHrP has been shown to have a broad range of effects on cellular proliferation and differentiation, on organ development and on transepithelial calcium transport. In almost every instance, these roles are paracrine or autocrine. The vascular biology of PTHrP is currently one of the most active areas of investigation in the PTHrP field. PTHrP has been shown to be a potent relaxant in every type of smooth muscle including gastrointestinal [13, 14] , bladder [15] , uterine [16] , and, importantly in the current context, aortic [17] , coronary [18] and renal arterial [19] smooth muscle. We have previously demonstrated that PTHrP causes dilation of the renal arterial tree in intact rabbit and rat kidneys [7, 20] . These actions are also observed in the in situ hydronephrotic model as well. Studies in this latter model demonstrate that PTHrP dilates the preglomerular vessels without affecting the efferent arteriole, and that after inhibition of angiotensin converting enzyme PTHrP dilates both pre-and post-glomerular arterioles [21] . A direct stimulatory effect on renin release has also been shown [22] . These findings, together with the observations that PTHrP is produced locally within every type of smooth muscle examined so far (aortic, carotid, uterine, bladder, gastric), suggest that PTHrP is likely to serve in a paracrine/autocrine fashion within the renovascular tree and may play a physiologic role in the momentto-moment regulation of renovascular tone.
Evidence that PTH stimulates cAMP production in extrarenal [23] [24] [25] [26] [27] [28] as well as intrarenal [29, 30] vascular smooth muscle cells has accumulated. Thus a role for cAMP as a second messenger for the effect of PTHrP in vascular smooth muscle cells appears plausible. Indeed, PTHrP(1-34) increases cAMP production in rat aortic smooth muscle cells [31, 32] . In rat aortic spiral strip preparations, a direct cause-and-effect relationship between cAMP production and the decrease of isometric tension by PTHrP has been demonstrated [33] . On the other hand, PTHrP(1-34) did not alter tissue cAMP level in the rabbit renal arteries [19] . In isolated renal arterioles, PTHrP has been shown to stimulate adenylyl cyclase activity with an EC50 value in the nanomolar range [291. However, a direct cause-and-effect relationship between adenylyl cyclase stimulation and renal vasodilation in response to PTHrP has not yet been demonstrated. While the evidence linking cAMP to PTHrP-mediated renovascular relaxation is reasonably secure, the question as to whether the vasodilatory action of PTHrP involves endothelium-derived nitric oxide (NO) signaling pathway, surprisingly has received less attention. The relaxant effect of PTH in isolated rat aorta and mesenteric vasculature does not require an intact endothelium and appears to result from a direct effect on the vessel medial layer [26] . On the other hand, in porcine coronary arteries, removal of endothelial cells or pretreatment with nitro-L-arginine, a NO-synthase inhibitor, impaired, although to a small extent, PTH-induced relaxations [34] . In the isolated rabbit kidney we have previously shown that the inhibition of NO-synthase by L-NAME markedly reduced the PTHrP-induced relaxation [20] . In this latter study, the question as to whether the renal vascular relaxation induced by PTHrP requires an intact endothelium was not explored.
The current studies have two specific goals. First, to demonstrate that PTHrP has the potential for playing a local physiologic role, we wanted to determine whether PTHrP, which is known to be produced in other vascular smooth muscle beds, is actually produced within the intrarenal arterial tree. For these studies, we chose to examine the normal human kidney, since we have previously described the distribution of PTHrP in the rodent kidney [35] . In that prior study, we examined neither the vascular tree nor the macula densa for expression of PTHrP. The present study also attempted to explore the role of the adenylyl cyclase! protein kinase A and the endothelium/NO!guanylyl cyclase pathways in the renovasodilatory response to PTHrP and to determine the interaction between these signal transduction systems. For these studies we used the rabbit kidney.
Methods
Sources and preparations of drugs The following synthetic peptides were obtained from Bachem 
Immunohistological studies
For these studies, we elected to use normal human kidney, since we have previously described the immunohistological staining pattern in the rat kidney [36] . The results shown are from one kidney but are representative of sections obtained from multiple human kidneys. Healthy kidney was obtained from the unaffected upper or lower poles of surgical specimens resected from patients with hypernephroma [36] , with the exception that immunoperoxidase-labeled second antisera were employed in place of fluorescence-labeled antisera. For immunodetection of PTHrP, sections were deparaffined and stained as described previously [361 using immunoaffinity-purified rabbit antisera that recognize both PTHrP and PTHrP(37-74) as well as intact full-length PTHrP(1 -74). Avidin-biotin complex immunoperoxidase was used for detection. Two types of control were used, and included staining in the absence of primary antibody, and staining in the presence of primary antibody which had been pre-incubated with PTHrP or PTHrP(37-74) as appropriate [35, 36] . Previous studies have shown that the region-specific PTHrP antisera used in the present study are highly specific and do not cross-react with PTH(1-84) or PTH(1-34) [37, 38] .
Isolation and perfusion of rabbit kidney
Male and female New Zealand rabbits (2 to 2.2 kg) were anaesthetized with tiletamine-zolazepam (Zoletil® 75 mg/kg i.m.; Reading Laboratories, Paris, France). The left renal artery was catheterized in situ with a dual-lumen 18G catheter (Sherwood Medical, Tullamore, Republic of Ireland) allowing both the perfusion of the kidney and the recording of perfusion pressure.
The left kidney was then removed from the animal and the perfusion was pursued in vitro exactly as described before [20] . The perfusion medium was a Krebs-bicarbonate solution, pH 7.4 containing 30 g/liter modified gelatine as an oncotic agent, and (in iO M): Na (150), K (5) Mg24 (1.5), Ca2 (1.5), lactate (30), glucose (11) and NaHCO3 (24) . The perfusion flow was adjusted to 4 ml/min/g of contralateral kidney, representing an overall mean flow of 36.1 0.6 mI/mm (N = 66), in accordance with the physiological renal blood flow measured in anaesthetized rabbits [39] , and was kept constant throughout the experiments. All perfusions were performed in the presence of iO M indomethacm to rule out the involvement of vasoactive prostaglandins with agonist-induced relaxations. As the isolated kidney has little if any vasoconstrictor tone under basal resting conditions, vascular tone was raised after an equilibration period, with Nad as indicated below. All agonist or drug concentrations are given as final concentrations in the perfusate. recirculating perfusion circuit. The recirculating perfusate volume was 72 ml. After a 50-minute equilibration period, kidney preparations were preconstrieted with a continuous infusion of Nad in the recirculating circuit. A rate of 75 nmol/min was necessary to obtain a sustained preconstriction and caused an increase in mean renal perfusion pressure from about 40 mm Hg to values of 200 mm Hg. The relaxation rates induced successively by 10 hPTHrP(1-34), 2 X 10 6 M Bk or 10 M Ach, and 2.5 X io-M Fsk, were studied under basal conditions or after administration of the pharmacological tools used to inhibit various signaling pathways or to damage endothelium. For clarity, the protocols used and the number of kidney preparations performed in each of the 12 independent experimental groups are depicted in Figure 1 .
Desensitization of PTJ-frP-induced vasorelaxation in the isolated perfused rabbit kidney The recirculating closed circuit design does not allow accurate control of the duration of exposure to the peptides. Therefore, for desensitization experiments, the kidney preparations were perfused in a single-pass open circuit system. After an initial equilibrating period of 50 minutes, the preconstricted state was induced as above by iO-M Nad added to the perfusate. PTHrP(1-34) was directly infused into the renal artery catheter, in close proximity to the kidney, over periods of 1 or five minutes to yield a concentration of 10_Il or 5 >< 10 M in the perfusate. After a peptide-free interval of 10 minutes, rechallenge with 5 X 10_8 M PTHrP was performed over a period of one minute.
Renal microvessel adenylyl cyclase desensitization
Rabbit renal microvessels were prepared in three successive steps as described previously [29, 40] including the collagenase digestion of renal interstitial tissue and dispersion of the renal cortex into tubules, glomeruli and microvessels, the removal of all glomeruli and a portion of the tubules by sieving the dissociated cortical suspension through 125 and 70 m sieves, and the centrifugation of the crude microvessels thus obtained on hypertonic three-step sucrose gradients to achieve separation between remaining tubules and the microvessels. Based on morphological, biochemical, physiological and pharmacological criteria, this microvessel fraction is pure and is distinct from the tubules [8, 29, 40] .
For desensitization experiments, microvessels obtained from 4 to 12 kidneys in bicarbonate-Ringer buffer, pH 7.4, containing (in 10 3M): NaCI (101) KC1 (7); CaC12 (1.5); MgSO4 (1.2); NaH2PO4 (1.2); NaHCO3 (17.5); sucrose (34) and glucose (11) were exposed under continuous stirring and bubbling with 95% 02-5% CO2 to PTH, PTHrP and agonists, for 10 minutes at 37°C. Control treatments were performed under identical conditions, except that buffer with no agonist was used. The treatment suspensions were then cooled and washed twice with fresh buffer and naive, control or agonist-treated microvessel homogenates containing 4 j.tg protein, were incubated at 30°C for 30 minutes in a total volume of 200 .tl for adenylyl cyclase measurement, as described previously [29] .
Expression of the results and statistical analysis
Vasoactive responses to the drugs were expressed as maximal percent change of the Nad-induced constriction. Adenylyl cyclase activity was expressed as pmoles cAMP produced/mm/mg protein.
All data were represented as mean SEM. Analysis of variance and Duncan's multiple range test were used to test for statistical significance between the various experimental conditions. In all cases, the significance level was set to P < 0.05.
Results
Immunohistological localization of PTHrP in the human kidney
As can be seen in Figure 2 , PTHrP was detected in multiple sites within the human kidney using the PTHrP (37-74) antiserum. Similar results were observed using the PTHrP(1-36) antiserum. These sites correspond well with the localization described previously in the rat kidney [36] and include the proximal and distal tubules, the collecting duct, and the visceral and parietal epithelial cells within the glomerulus ( Fig. 2A-F) . As in the rat, no PTHrP was observed in mesangial cells. Importantly in the current context, PTHrP was identified throughout the renal arterial tree, from the arcuate (Fig. 2H ) and interlobular arteries (Fig 2 F, G) through the afferent and efferent arterioles ( Fig. 2A-F) . In the vascular system, PTHrP was observed both in the smooth muscle of the media as well as in the endothelium (Fig. 2 A-C, G, H) . As can be seen in Figure 2E , staining was particularly apparent in the macula densa in contact with the adjacent arterial wall. PTHrP staining was specific in that: (1) preincubation of the primary antiserum with PTHrP as described in the Methods section abolished the staining (Fig. 2L) ; and (2) elimination of the primary antiserum also led to absence of staining (not shown).
Protein kinase A-and adenylyl cyclase-dependence of PTHrPinduced vasorelaxation in the rabbit isolated kidney A continuous infusion of 75 nmol/min of Nad into the recirculating perfusate was necessary to obtain a stable and sustained preconstriction over a period of 80 minutes (Methods; Fig. 1 ) and caused an increase in mean renal perfusion pressure from about 40 mm Hg to values of about 190 mm Hg. We have shown previously under very similar conditions that this relatively high renal tonus does not affect the relative relaxant response to and Ach in the isolated rabbit kidney [20] . In these studies we checked that the relaxant responses to PTHrP and Ach are strictly proportional to the preconstriction level for perfusion pressures that ranged between 90 and 240 mm Hg.
(Rp)-cAMPS has been shown to directly inhibit cAMP-dependent protein kinase [41, 42] . We employed this compound to determine whether the activation of protein kinase A is directly linked to the PTHrP(1-34)-induced vasorelaxation of the preconstricted isolated kidney (groups 2 and 5 in Fig. 1 ). We compared PTHrP(1-34) with Fsk, a cAMP-dependent vasodilator [43] and Ach, a NO-dependent, cAMP-independent renal vasodilator. (Fig. 3 B, D) . In absence of (Rp)-cAMPS, the maximal percent decrease of the Nad-induced constriction produced by PTHrP(1-34), Fsk and Ach were 35.2 2.2%, 55.1 2.5% and 28.8 5.0%, respectively (Fig. 4) . The addition of (Rp)-cAMPS to the recirculating perfusate significantly reduced, but did not completely prevent, the PTHrP(1-34)-and Fsk-induced vasorelaxation by 57% and 53%, respectively. As expected, Ach-induced vasorelaxation was not significantly affected by (Rp)-cAMPS.
Since we have previously shown that NO-synthase inhibition markedly reduced PTHrP-induced vasorelaxation in the rabbit kidney [20] , we then asked whether or not the combined effect of L-NAME, a specific NO-synthase inhibitor, and (Rp)-cAMPS would be additive. The Nad-induced preconstriction was further increased by io-M L-NAME with maximal percent increase of 16.2 4.4% in Figure 3C and by 20.4 5.3% in Figure 3D . L-NAME markedly reduced, but again did not completely prevent, the hPTHrP(1-34)-and Ach-induced relaxation, by 71% and 63%, respectively (Fig. 4) . Conversely, the Fsk-induced relaxation was not significantly affected by L-NAME. The combined effect of (Rp)-cAMPS and L-NAME on PTHrP(1-34)-induced relaxation was similar to the effect of each compound added separately.
Regarding Fsk-and Ach-induced relaxations, the combined effect of the inhibitors was the same as the effect of either (Rp)-cAMPS or L-NAME, respectively.
To further explore the involvement of the adenylyl cyclase pathway, we compared the desensitization of PTHrP(1-34)-induced vasorelaxation of the preconstricted isolated rabbit kidney and PTHrP(1-34)-stimulated adenylyl cyclase pathway in isolated rabbit renal microvessels. 2.6% fall in perfusion pressure (Fig. 5A ). Exposure to 5 >< 1O M PTHrP(1-34) for one or five minutes resulted in 42.6 1.4 and 36.2 3.5% reduction in perfusion pressure, respectively (Fig. 5 B, C) . The desensitizing effect of these peptide infusions on the vasorelaxation produced by a second one minute-S X i0 M infusion was measured after a peptide-free interval of 10 minutes. The one or five minute 1.5%, respectively (Fig. 5D ). Exposure to M PTHrP(1-34) during one minute was able to significantly desensitize, by 16.4 4.0%, the response to the second one-minute 5 X 10 M infusion of peptide. Figure 6A shows the effect of treating homogenates derived from microvessels purified from rabbit renal cortex for 10 minutes, with increasing concentrations of rPTH(1-34) on the PTH concentration-response curve for adenylyl cyclase stimulation. The EC5 value for adenylyl cyclase stimulation in control untreated vessels was 1.3 0.6 n, and the lowest concentration of PTH producing a significant stimulation was 10'° M. However, exposure to a concentration of PTH as low as lO M significantly reduced the maximal effect observed with control-untreated vessels by 24.7 2.3%. Exposures to 10 or i0 M PTH reduced the maximal effect of the subsequent dose-response curve by 43.3 5.4 and 58.8 4.6%, respectively. On the other hand, the EC50 value was not significantly affected by PTII-induced desen- whether protein kinase A is involved in the desensitization process, crude microvessels were treated for 10 minutes with the direct adenylyl cyclase stimulant Fsk [43] , or the membrane permeable cAMP analogue, dibutyryl-cAMP. Figure 6B shows that neither maneuver blunted the responsiveness of microvessel adenylyl cyclase to rPTH or PTHrP . In contrast, dibutyryl-cAMP had a paradoxical sensitizing, or potentiating effect on rPTH(1-34) hut not on PTHrP(1-34)-responsive adenylyl cyclase.
NO/NO -synthase-dependence of PTHrP-induced vasorelaxation in the isolated rabbit kidney The next series of studies was directed at the NO/NO-synthase system. Specifically, we examined the effects of i0 M L-NAME, of i0-M carboxy-PTIO (a NO scavenger), and of iO M MB (a soluble guanylyl cyclase inhibitor) on PTHrP(I-34)-induced vasorelaxation (groups 1, 3, 7 and 8 in Fig. 1 ) in isolated recirculating perfused kidneys preconstricted with Nad. We compared PTHrP to 2 X 10 vi Bk (a renal vasodilator which, in the absence of the prostaglandin stimulatory pathway, acts solely through the formation of NO [44, 451) and to 2.5 X iO vi Fsk. In these series of experiments, the maximum vasoconstrictor effects of L-NAME, MB and earboxy-PTIO, on the Nad-induced preconstriction were 27.0 1.3%, 17.4 5.1% and 14.1 4.7%, respectively (profiles of perfusion pressure changes not shown). In the absence of inhibitor, the vasorelaxation produced by PTHrP(1-34), Bk and Fsk were 36.3 2.3%, 17.6 3.2% and 55.6
1.4%, respectively (Fig. 7) . The addition of L-NAME, carboxy-PTIO or MB significantly reduced, hut did not completely prevent, the PTHrP-induced vasorelaxation, by 57%, 27% and 34%, respectively, and abolished the Bk-induced vasorelaxation. As expected, Fsk-induced vasorelaxation was not significantly altered by these maneuvers.
Endothelium dependence of PTHrP-induced vasorelaxation in the isolated rabbit kidney
The next experiments were performed to ask whether the endothelium is required for the renal vasodilatory action of PTHrP. Three different approaches were used to damage endothelium of the preconstricted recirculating kidneys or to block endothelium-derived NO (groups 9 to 11 in Fig. 1 As shown in Figure 8 , none of these treatments was able to significantly alter PTHrP-nor Fsk-induced vasorelaxation. In contrast, all these treatments markedly reduced Bk-induced vasorelaxation by 69% (gossypol), 92% (CHAPS) and 53% (F8rAg-ab + cpmt). L-NAME similarly affected PTHrP-induced vasorelaxation, whether the kidneys were pretreated with F8rAg-ab + cpmt or not (67% vs. 53% in groups 9 and 12, respectively). In contrast, L-NAME further inhibited and thereby virtually abolished the Bk-induced vasorelaxation that persisted after pretreatment with F8rAg-ab + cpmt. Pretreatment with F8rAg-ab + cpmt significantly reduced the vasoconstrictory effect of L-NAME on the Nad-induced preconstriction from 21.3 2.7% (mean effect of L-NAME in groups 3, 4 and 6; N = 13) to 13.6 1.4% (in group 12).
Discussion
Immunohistological localization of PTHrP in human renal vasculature
Immunostaining in glomerular epithelial and tubular cells of the rat kidney has previously been reported [36] . Since PTHrP is present in most other arterial systems [461, it appeared highly likely that PTHrP is produced in the renal arterial tree, but this had not been specifically documented. In the current study, PTHrP was found to be present throughout the entire intrarenal vascular network in humans, including the arterioles near the glomerulus and the larger interlohular and arcuate arteries. arterioles [8] . Thus, the ubiquitous distribution of PTHrP within the juxtaglomerular apparatus, together with the previous observations demonstrating that PTHrP is produced in the glomerular epithelial cells, strongly suggest that PTHrP may participate in the regulation of glomerular blood flow. Direct demonstration of such a role within the glomerulus and in adjacent vessels will require further studies.
Role of cAMP-dependent signaling pathway in PTHrP-induced vasodilation in the isolated rabbit kidney A number of laboratories have shown that (Rp)-cAMPS is a useful tool for distinguishing between protein kinase A-dependent and protein kinase A-independent events, as for example PTH/ PTHrP-induced bone resorption [48] or PTHrP-induced aortic relaxation [33] . The present results reveal that in the isolated rabbit kidney preconstricted with Nad, (Rp)-cAMPS comparably inhibited the vasorelaxation by PTHrP(1-34) and by Fsk, a direct activator of adenylyl cyclase [43] . It seems unlikely that such inhibitory effect of (Rp)-cAMPS is nonspecific or toxic, because (Rp)-cAMPS did not affect Ach-induced vasorelaxation. However, neither PTHrP-nor Fsk-induced vasorelaxation was completely blocked by (Rp)-cAMPS. It is possible that the concentration of (Rp)-cAMPS used (i0-M) or incomplete membrane permeability prevented complete inhibition of PTHrP-and Fskinduced vasorelaxation. Inasmuch as Fsk-induced vasorelaxation is exclusively dependent upon the activation of protein kinase A, and based on the similarity of the inhibitory effect of (Rp)-cAMPS on Fsk-and PTHrP-induced vasorelaxation, an important conclusion of the present study is that the activation of protein kinase A signaling pathway plays a major role in the dilatory effect of PTHrP in the renovascular system. To further explore the cAMP-dependence, we asked whether the desensitization of PTHrP(1-34)-induced vasorelaxation in the isolated rabbit kidney would parallel desensitization of PTHrP(1-34)-stimulated adenylyl cyclase in isolated rabbit renal microvessels. Such desensitization of PTHrP( 1-34)-induced renovascular actions has not yet been reported. We found that renal vasorelaxation responded within 10 minutes to short-term (1 to 5 mm) treatment with PTHrP(1 -34) by a state of refractoriness to the peptides. Desensitization was both time-and concentration-dependent. Further, treatment with either PTHrP(i-34) or PTH peptides desensitized both PTH-and PTHrP-responsive adenylyl cyclase. The extent of tachyphylaxis to the vasorelaxing effect of PTH/PTHrP closely paralleled the extent of desensitization of PTH/PTHrP-responsive adenylyl cyclase in isolated rabbit renal microvessels. Indeed, in renal microvessels, 10-minute treatment with a concentration as low as l0 M or with io-M of PTH reduced by 25 and 60%, respectively, the subsequent maximal adenylyl cyclase response to i0 M of PTH. Accordingly, exposure of the isolated perfused kidney to M PTHrP for five minutes, or to 5 X 10 M for one minute, reduced by 16 and 55%, respectively, the vasodilatory response to rechallenge with 5 X 10-8 M PTHrP, 10 minutes later. These results further identify cAMP as a key signaling pathway of PTH/PTHrP-induced renal vasodilation. We also found that treatment with PTH peptides resulted in more substantial desensitization for both PTH-and PTHrP-responsive adenylyl cyclase than treatment with PTHrP. The significance of these findings is unclear. It is tempting to speculate that protein kinase A activation may have mediated desensitization by phosphorylating the PTH/PTHrP receptor. However, Fsk, a direct adenylyl cyclase stimulant, or the membrane permeable cAMP analogue, dibutyryl-cAMP, were unable to inhibit subsequent adenylyl cyclase responsiveness to rPTH or PTHrP(1-34). Moreover, 10" at PTH, which had no detectable effect on adenylyl cyclase activity, was still able to desensitize maximal-stimulated enzyme activity. Together, these results rather suggest that desensitization is a cAMP/protein kinase A-independent process. The question as to whether the phospholipase C/protein kinase C may play some role in the PTHrP-mediated renal vasodilation, perhaps with regard to receptor desensitization, will need further investigations. The current results also indicate that the decline of subsequent adenylyl cyclase responsiveness was PTH/PTHrP-specific and therefore represented a homologous desensitization. This latter conclusion is supported by recent findings from other laboratories on extrarenal cultured vascular smooth muscle cells. Indeed, treatment of aortic or mesenteric smooth muscle cells with Fsk or isoproterenol in concentrations known to markedly increase cAMP did not affect the subsequent cAMP response to PTH [27, 49] .
Role of nitric oxide-dependent signaling pathway in PTHrPinduced vasodilation in the isolated rabbit kidney
In a previous study [20] , we showed that a component of the vasorelaxant effect of PTHrP in the isolated perfused rabbit kidney was inhibited by L-NAME. Therefore, in addition to cAMP, a substantial part of the renodilatory effect of PTHrP might also be dependent upon the formation of NO. In the present experiments, we extended these results by testing the effect of maneuvers that interfere not only with the formation of NO, but also with the action of NO. Carboxy-PTIO is an oxygen donor for NO, which has been shown to react with NO, more than 10-fold faster than does molecular oxygen, and yields NO2 in a stoechiometric manner in solutions, thus scavenging and inactivating NO [50] . MB, which inhibits soluble guanylyl cyclase probably by interaction with the heme group of the enzyme [51] , prevents the rise in cGMP and the action of NO on target smooth muscle cells. Like L-NAME, carboxy-PTIO and MB caused an increase of the vasoconstriction induced by Nad. Importantly, these observations provide additional support for an involvement of NO in the regulation of basal renal vascular tone [44] .
L-NAME did not completely antagonize PTHrP-and Ach-induced vasorelaxation, although it completely blocked Bk-induced vasorelaxation in the absence of the cyclooxygenase-dependent pathway. The present study also revealed that as with NO formation, pharmacological blockade of NO action markedly decreased PTHrP-induced vasorelaxation in the preconstricted isolated perfused rabbit kidneys. As for L-NAME, these maneuvers did not completely antagonize PTHrP-induced vasorelaxation, although they completely blocked Bk-induced vasorelaxation. It seems improbable that the renovascular system contains different PTHrP receptor subtypes mediating the stimulation of different second messenger pathways since the combined effect of near-maximal concentrations of L-NAME and (Rp)-cAMPS was not additive. Additionally, L-NAME, carboxy-PTIO and MB had higher inhibitory effect on Bk-induced vasorelaxation than on PTHrP-induced vasorelaxation, whereas (Rp)-cAMPS comparably inhibited Fsk-and PTHrP-induced renal vasorelaxation.
Therefore, NO-synthase/NO/guanylyl cyclase inhibition presumably block PTHrP-induced vasorelaxation to a lesser degree than protein kinase A inhibition. In support of this, both a marked increase of cAMP and a small increase of cGMP were seen in rabbit aortic strips during PTH-induced relaxation [24] , indicating that at least two mechanisms of cyclic nucleotidc-smooth muscle relaxation coupling may be present in this system. These observations are consistent with the concept that cAMP is essential to trigger the vasorelaxation in response to PTHrP and that the activation of NO-synthase might be secondary to the activation of adenylyl cyclase. At this point, it may be concluded that PTE-IrPmediated renal vasorelaxation presumably involves a complex signal transduction pathway or combination of pathways involving the formation of cAMP, NO and cGMP. This issue will he further discussed below in the light of the results indicating that the cAMP/NO-dependent PTHrP-induced renal vasodilation does actually not require an intact endothelium.
Role of endothelium in PTHrP-induced vasodilation in the isolated rabbit kidney
The role of the endothelium in PTHrP-induced vasorelaxation has received relatively little attention. The observations described above demonstrating NO-dependency of the renodilatory action of PTHrP and the presence of PTHrP in endothelial cells strongly suggest that an endothelium-mediated pathway may exist. Recent studies show that the two constitutive NO-synthase isoforms (endothelial or type III and neuronal or type I) are widely distributed throughout the kidney of various species. Indeed, constitutive NO-synthase is expressed not only in the endothelium of the whole glomerulo-arteriolar network, but also in mesangium and tubular cells including the macula densa [52] [53] [54] [55] . Therefore experiments were performed to explore whether the endothelium was required for the renal vasodilatory action of PTHrP. Because the endothelium cannot be readily removed from the microvasculature of intact kidney, we used three different approaches to damage endothelium or block endothelium-derived NO. The first approach is based on the fact that endothelial cells specifically express factor Vill-related antigens and that complement reacts with F8rAg-ab/antigen complexes, causing cell damage and lysis [56] . This method has been shown to selectively eliminate endothelium-dependent vasodilation from microperfused glomerular afferent arteriole without damaging vascular smooth muscle cells [56] . For the second approach, gossypol was used. Gossypol is believed to inhibit the release and/or the production of endothehum-derived NO in the isolated perfused rat kidney [44, 57] . For the third approach, the detergent, CHAPS, was used, which has also been used previously to remove endothelium in the isolated perfused rat kidney [44, 58] . These treatments did not seem to impair renal smooth muscle responsiveness, since they affected neither the Nad-induced constriction, nor the Fsk-induced relaxation. None of the three endothelium-damaging techniques influenced the renovasodilatory response to PTHrP. In contrast, all three markedly decreased Bk-induced vasorelaxation. These findings support the conclusion that PTHrP does not require an intact endothelium to induce vasorelaxation in the kidney, despite the involvement of a NO-dependent signaling pathway. If this is true, then L-NAME should be able to reduce PTHrP-induced vasorelaxation whether an intact endothelium is present or not. Indeed, the inhibitory effect of L-NAME on PTHrP-induced vasorelaxation was not altered by pretreatment of the kidneys with the endothelial antibody, F8rAg-ab + cpmt, although this treatment abolished the Bk-induced vasorelaxation. It should be stressed that the effects of the three different methods used to damage endothelium were consistent, although the actual degree of endothelium damage is difficult to determine.
Together, these results would simply imply that the L-NAME sensitivity of PTHrP-induced vasorelaxation resulted from inhibition of an extraendothehial NO-synthase pool, namely smooth muscle and/or tubular cell NO-synthase. There has been recent evidence that the gene of inducible isoform of NO-synthase (type II) is up-regulated by cAMP [59] and cGMP [601 in vascular smooth muscle cells. Moreover, treatment of vascular smooth muscle cells with Fsk has been shown to induce GTP:cyclohydrolase mRNA expression, the regulatory enzyme of tetrahydrobiopterm synthesis, the latter heing a required cofactor for NOsynthase activity [61] . However, such mechanisms seem improbable under the present experimental conditions since up-regulation of inducible NO-synthase in smooth muscle cells requires several hours. Moreover, it is noteworthy that phosphorylation of purified constitutive NO-synthase from brain by protein kinase A does not alter its activity [62] . Finally, constitutive isoforms of NO-synthase (type I or III) have not been detected in the muscle layer of the intrarenal vascular network [54] . At this point it appears therefore unlikely that the sensitivity to L-NAME of PTHrP-induced vasorelaxation resulted from inhibition of a NO-synthase pool originating in the vascular smooth muscle cells. Since strong presence of NO-synthase type I has been found in macula densa as well as in the thick ascending limb [54] , it is tempting to speculate that the L-NAME sensitivity of PTHrPinduced vasorelaxation resulted from inhibition of a tubular cell NO-synthase. Obviously, further studies are necessary to claril the extra-endothelial origin of the NO/cAMP-mediated vasodilation induced by PTHrP in the kidney.
In summary, immunohistologic studies reveal that PTHrP is present throughout the juxtaglomerular apparatus and along the entire human renal vasculature, in both media and intima. Furthermore, the present study indicates the direct involvement of the cAMP/protein kinase A system and a contributory role of NO/guanylyl cyclase system in the signal transduction system mediating the vasodilatory action of PTHrP in the isolated perfused rabbit kidney prteconstricted with Nad. Although PTHrP is produced in renovascular endothelial cells, the in vitro vasodilatory action of PTHrP in the kidney presumably does not require an intact endothelium, which strongly suggests the involvement of an extra-endothelial signal transduction pathway implicating both cAMP/protein kinase A and NO/guanylyl cyclase systems.
In extra-renal vascular beds PTHrP has been repeatedly demonstrated to be vasorelaxant and to be present in both smooth muscle and endothelial cells. Moreover, the major serum factor responsible for the induction of PTHrP in vascular smooth muscles appears to be angiotensin II. Further, PTHrP has repeatedly been shown to be induced by mechanical stretch in vascular and extra-vascular smooth muscle cells (detailed references on these issues are in [12] ). The question as to whether angiotensin II, a key factor in the regulation of renal hemodynamics, or mechanical stretch (or increases in renal perfusion pressure) are able to up-regulate PTHrP production within the renal gbmerulo-vascular tree has not been addressed to date. Our previous findings demonstrated that PTHrP at physiological concentrations dilates the renal vascular tree under both in vivo and in vitro conditions [7, 9, 20, 21, 63] , increases renal blood flow [63] , single glomerulus flow [21] and glomerular filtration rate [63] , and causes a dramatic increase in the release of renin from juxtaglomerular cells [10] . From the present study it appears that PTHrP is actually produced within the renal vascular tree and has a place among the substances whose reno-vasodilatory actions implicate NO generation, another key factor in the regulation of renal hemodynamics [44, 51, 55, 57, 58] . Collectively, these findings invite the speculation that PTHrP could play a significant modulatory role in maintaining renal blood flow. Clearly, much more work needs to be done for the understanding of the normal physiological roles of PTHrP in the renovascular system.
